Robino1 wrote:Question: I notice that there are different locations, is it possible to go to a location to get the same trial experience or is it better to go with a major cancer center listed in the top 10 in the country? (like Sloan Kettering)
Yes, you are correct. This is the trial that Mr Ziggy is on. However, it is not possible to guarantee in any way that you would get the same trial experience.
The main reason is that this is a Phase 3 randomized clinical trial (RCT) with three arms. If you enroll in this trial at any of the 190 available centers, you will first be randomized to one of the three available treatment groups. There is no guarantee that you will be assigned to.the first group (the three-drug combo group that Mr Ziggy is in). You might be assigned to one of the other two groups. You or your doctor cannot choose which group you are assigned to. This is done automatically by random assignment. This is the way that Phase 3 trials work.
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib + binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.
You can read about Phase 3 trials in this booklet on Clinical Trials written by Dr. Tom Marsilje, particularly page 11, which explains why you have no choice in treatment option for Phase 3 trials. The only choice you have in Phase 3 trials is to drop out of the trial if you are assigned to a group that you don't like:https://5xlhc2qz20k3jc6dy3g31xb4-wpengine.netdna-ssl.com/wp-content/uploads/2017/10/ClinicalTrials_MiniMag_2017.pdf
"...Patients in RCTs can’t choose their treatment, nor can their doctors..." (page 18)
Zig2017 wrote:It has 3 arms to the trial - one is a control arm, one has two drugs used to target BRAF and MEK inhibitor, and another arm has the three drug combo used to target EGFR, BRAF and the MEK signaling pathway. He starts Tuesday Nov. 28th and was randomized to get the 3 drugs Encorafenab, Binimetinib, Cetux (spelling might be wrong, sorry). Dr. Rona Yaeger is heading it up.